Eleva Capital’s Esperion Therapeutics ESPR Stock Holding History

Eleva Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-183,047	Closed	-$502K	–	32
2026 Q2	$502K	Hold	183,047	–	–	0.15%	16
2026 Q1	$502K	Buy	+183,047	New	+$579K	0.15%	16

Eleva Capital's ESPR Position: Q3 2026 in Review

Eleva Capital sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 183,047 shares — an estimated $502K sold.

Eleva Capital first reported a position in ESPR in Q1 2026 and held it in 2 quarters. The position peaked at $502K in Q2 2026. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

Eleva Capital reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
Eleva Capital sold 183,047 Esperion Therapeutics shares in Q3 2026, an estimated $502K.
Eleva Capital first reported a position in Esperion Therapeutics in Q1 2026 and held it in 2 quarters.
Eleva Capital's Esperion Therapeutics position peaked at $502K in Q2 2026.
0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Eleva Capital's 13F filing for Q3 2026, filed 6 Oct 2026.